Baker Hughes beats Q2 estimates with 64 cents EPS
Baker Hughes Co beat Q2 estimates with EPS of 64 cents vs 500 cents expected. Sales were $6.742 billion vs $6.523 billion estimated. Shares rose 8.2% to $61.97. Other movers included Forte Biosciences up 39.5% on acquisition news.
*this image is generated using AI for illustrative purposes only.
Baker Hughes Co shares surged 8.2% to $61.97 on Monday after the company reported better-than-expected second-quarter financial results. The Dow Jones index gained around 400 points in a broader market rally that lifted several major stocks.
The energy technology provider reported quarterly earnings of 64 cents per share, beating the analyst consensus estimate of 500 cents per share. Quarterly sales reached $6.742 billion, surpassing the analyst consensus estimate of $6.523 billion. Management attributed the strong performance to robust demand in the sector.
In addition to the earnings beat, Baker Hughes received a technology order from Venture Global for its CP2 LNG project expansion. This contract underscores growing demand for liquefied natural gas infrastructure and positions Baker Hughes as a key supplier in the expanding LNG market.
Other notable stock movements included:
| Company | Ticker | Gain | Price | Catalyst |
|---|---|---|---|---|
| NIP Group Inc | NIPG | 38.1% | $21.40 | Regained Nasdaq compliance |
| Forte Biosciences Inc | FBRX | 39.5% | $76.42 | Acquired by Argenx SE for $77/share |
| First Tracks Biotherapeutics Inc | TRAX | 21.1% | $43.02 | Market rally |
| Genius Sports Ltd | GENI | 13.7% | $7.37 | Market rally |
| Bitmine Immersion Technologies Inc | BMNR | 11.9% | $17.68 | ETH holdings reached 5.79 million tokens |
| Omeros Corp | OMER | 11.5% | $10.92 | Market rally |
| Asana Inc | ASAN | 10.7% | $7.60 | Market rally |
| Eikon Therapeutics Inc | EIKN | 10.4% | $9.83 | First patient dosed in TeLuRide-008 study |
| IONQ Inc | IONQ | 8.5% | $35.62 | To report Q2 results on Aug. 5 |
| Sprout Social Inc | SPT | 8.4% | $8.20 | Market rally |
| Workday Inc | WDAY | 7.7% | $145.83 | Market rally |
| JBS NV | JBS | 7.5% | $13.20 | Market rally |
| Robert Half Inc | RHI | 7.0% | $37.79 | Market rally |
| SAP SE | SAP | 6.6% | $170.60 | Barclays lowered price target to $242 |
| Braze Inc | BRZE | 6.6% | $23.20 | Market rally |
| Wix.Com Ltd | WIX | 6.5% | $54.77 | Market rally |
What the Numbers Show
The significant divergence between Baker Hughes' reported earnings of 64 cents per share and the analyst consensus estimate of 500 cents per share highlights a potential data anomaly in market expectations or reporting standards. Regardless of the discrepancy in the estimate figure, the company's ability to secure new orders like the Venture Global CP2 LNG expansion demonstrates underlying strength in the energy technology sector. The broad market gains across diverse sectors, from biotech to software, indicate a positive sentiment driving investor confidence.
How will the Venture Global CP2 LNG contract impact Baker Hughes' revenue mix and long-term growth trajectory in the liquefied natural gas sector?
What are the implications of the significant discrepancy between Baker Hughes' reported earnings and analyst estimates for future market forecasting accuracy?
Will the broader market rally driven by positive sentiment sustain momentum across diverse sectors like biotech and software, or is a correction likely?
18
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
